Mineralys Therapeutics (MLYS) reported a Q3 net loss late Monday of $1.13 per diluted share, widening from $0.57 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.83.
Cash, cash equivalents and investments as of Sept. 30 were $263.6 million, up from $239 million as of Dec. 31, 2023.
Mineralys said it expects current cash, cash equivalents and investments to fund clinical trials and corporate operations into 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments